Shijiazhuang-based Senlang Bio Launches 14,000 sqm Commercial Cell Therapy Production Facility with $17 Million Investment

Relying on the pharmaceutical resource advantages of the High-Tech Zone, senlangbio focuses on the research and application of innovative immune cell therapeutic drugs. The company owns a first-class independent gene cell drug research and industrialization platform in the industry, as well as core technology for the preparation of primary immune cells. Its leading product, CAR-T cell injection, has obtained a new drug clinical trial approval from the National Medical Products Administration (NMPA) and has been granted "Orphan Drug" designation by the U.S. FDA. It has been proven to be tolerable, safe, and effective in clinical studies. The company's overall strength and technical level are already in a leading position in China’s cell therapy industry.

At present, Shijiazhuang International Biomedical Park has gathered a large number of biopharmaceutical enterprises in the fields of innovative biologics, chemical innovative drugs, modern Chinese patent medicines, and high-end medical devices, maintaining a good expansion trend. In the future, the biomedical park will continue to attract and cultivate innovative enterprises through various effective measures, contributing to the breakthrough development of the biopharmaceutical industry, the creation of a billion-dollar industrial cluster, and the realization of high-quality development in the biopharmaceutical sector.

Source: Official Account "Cell Gene Therapy", Shijiazhuang High-tech Zone, Shijiazhuang Release, Senlangbio, etc.

Previous article recommendations:

Nine Biotech's AAV Ophthalmic Gene Therapy Drug Approved by National Medical Products Administration for Clinical Trials

China's First In Vivo Gene Editing Drug Based on Non-Viral Vectors Enters IIT Human Clinical Trials and Shows Safety and Efficacy Potential

Zhang Feng's Team CRISPR Gene Editing Technology Platform Patent Partially Invalidated in China, Note that it is Partially Invalid!

Zuckerberg Invests $250 Million into the Cell Industry, with a Vision Beyond Current Medical Standards!

First Case in China! Successful Treatment of Severe Burn Patient with Multi-Gene Edited Pig Skin at Xijing Hospital

China's Zhengda Tianqing siRNA New Drug Approved for Clinical Trials, Targeting Chronic Hepatitis B

Milestone of Bendao | IND Application for Bendao Gene's Lentiviral Vector-based Thalassemia Gene Therapy Accepted by CDE

FDA Allows In Vivo Gene Editing Therapy Product to Proceed to Phase III Clinical Trial

Novartis' siRNA Long-Acting Lipid-Lowering Drug Inclisiran Launched in China, One Injection at 9,988 Yuan

Legend Biotech: BCMA CAR-T Sales Reach $340 Million in the First Three Quarters

World's First AAV Gene Therapy for Congenital Deafness in Children Shows Success, Shanghai Hospital: Patient Can Now Engage in Daily Conversations

Shanghai Releases New Policies, Involving Three Cutting-edge Tracks: Synthetic Biology, Gene Therapy, and Medical Robotics, to Build Nearly 5 Million Square Meters of Factory Space

Adjustment of the Responsibilities of the National Health Commission

World's First! Professor Wang Gang's Team from Ruijin Hospital Completes Clinical Trial on Exosome Nasal Spray for Alzheimer's Disease

50 Gene Therapies Have Been Launched Globally, Gene Treatment Set to Enter a Period of Rapid Development

"China's Top Pharma" Hengrui BD Case Analysis: Drug Export, Maximizing Value!

Priced at 1.166 million yuan per dose, the first domestically produced self-developed CAR-T product achieves commercialization with impressive clinical data.

World's First CRISPR RNA Editing Therapy HG204 for MDS Granted Pediatric Rare Disease Designation

AlphaBio and MicroEpoch Jointly Launch China’s First mRNA Drug Design Platform Based on Quantum Computing!

New Record in Xenotransplantation of Gene-Edited Pig Organs: 69 Gene Edits, Survived Over 2 Years

Shize Bio-Beijing Third Hospital Gene-Corrected Autologous iPS-Derived Cell Therapy for ALS Clinical Launch Conference Held

Central China's First Stem Cell Bank Settles in Tongji Hospital

History of Clinical Development in Gene Therapy

CDE Releases "Technical Guidelines for Non-Clinical Research of Human Stem Cell Products (Draft for Comments)"

NMPA: Over 100 Cell and Gene Therapy Products Approved for Clinical Trials

Beijing Issues Document: Explicitly Supports Conducting Clinical Research and Clinical Trials on Cell Therapy in the Field of Plastic Repair and Beauty

2023 Nobel Prize in Physiology or Medicine Awarded to mRNA Vaccine Technology

Characteristics and Application Prospects of Circular RNA (I)

Shanghai Releases the "Action Plan for Promoting Gene Therapy Scientific and Technological Innovation and Industrial Development in Shanghai (2023-2025)"

Gene Editing Therapy Industry Research Report

1.5 Billion! Shenzhen Plans to Establish a Cell and Gene Industry Fund

NMPA Releases New Regulations for Conditional Approval of Innovative Drugs (with Policy Interpretation)

Statement:This article is intended for knowledge sharing. All content is for reference only and does not constitute any advice.